Richard Stefanacci, DO, MGH, MBA, AGSF, CMD—Column Editor
Craig Ornstein, PhD, MA
Uttama Rath, PhD, MS
Jamey Hardesty, MPH
Inclusion of oncology biosimilars in clinical pathways is one approach to reducing costs in this therapeutic area without compromising outcomes for cancer patients. There are currently eight Food and Drug...
Inclusion of oncology biosimilars in clinical pathways is one approach to reducing costs in this therapeutic area without compromising outcomes for cancer patients. There are currently eight Food and Drug...